NATCO Pharma Limited

“NATCO Pharma is a high-quality niche generics challenger with a proven Para IV franchise, near-debt-free balance sheet, and shareholder-aligned management — but it is a structurally lumpy business where earnings can collapse between exclusivity cycles, and the current price near 52-week highs at 29.7x forward P/E already embeds the next pipeline win materializing, leaving no margin of safety for new investors; the right action is to track it for a significant off-cycle correction before building a position.”